Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2376 - 2400 of 15640 in total
Approved
Matched Iupac: … 3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide Indium In-111 during imaging to evaluate...
Approved
Matched Description: … specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins …
Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect. Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S....
Approved
Investigational
Matched Description: … ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs …
Colestilan is an ingredient in the EMA-withdrawn product BindRen.
Approved
Investigational
Withdrawn
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses. Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment...
Approved
Investigational
Matched Description: … [A39201,A254177,L4615] It was later approved to be used in basal cell carcinoma and non-small non-small …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium. Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in...
Approved
Matched Description: … Toxoplasma gondii and Cryptosporidium. ... Resistant organisms include Enterobacteria, pseudomonads, and moulds. ... a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and
Matched Categories: … spiramycin and metronidazole ... Macrolides, Lincosamides and Streptogramins …
Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high...
Approved
Matched Description: … oral ingestion of certain medications or poisons by absorbing most drugs and toxins. ... It is used as a gastric decontaminant and emergency medication to treat poisonings following excessive ... passed over its surface to make a fine network of pores, producing a material with large surface area and
Matched Categories: … Antacids and Adsorbents ... Alimentary Tract and Metabolism …
Approved
Experimental
Matched Categories: … Antiinflammatory and Antirheumatic Products …
Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing...
Approved
Matched Description: … polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and ... to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Garlic allergenic extract is used in allergenic testing.
Approved
Nutraceutical
Matched Categories: … Herbs and Natural Products …
Papaya allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Herbs and Natural Products …
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. eculizumab, ravulizumab) which are effective in mitigating complement-mediated intravascular...
Approved
Investigational
Matched Description: … [A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. ... hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and ... Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …
Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis [FDA Label]. Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like...
Approved
Matched Description: … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and ... various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the Netherlands, and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Approved
Nutraceutical
Matched Categories: … Amino Acids, Peptides, and Proteins …
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Investigational
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express...
Approved
Matched Description: … It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular ... kill cancer cells, and are infused back into the patient. ... collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may...
Approved
Investigational
Matched Description: … triglyceride levels and liver and kidney dysfunction. ... [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines ... nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Vespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps the only viable option for reversing the anticoagulant effect of heparin use for over 77 years [A174778,...
Approved
Matched Description: … kidney tissue damage, and anaphylactic reaction, amongst others [A174778, L5371]. ... reversal predominantly via the formation of an inactive complex between the anionic nature of heparin and ... potential range in reversing all parenteral anticoagulants are sometimes considered high and limited …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Approved
Investigational
Withdrawn
Matched Description: … CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy...
Approved
Investigational
Matched Description: … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and ... approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Keyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet. Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such...
Approved
Investigational
Matched Description: … hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is...
Approved
Investigational
Matched Description: … [A218186, L32118] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit ... cardiac function and is invariably fatal. ... lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression...
Approved
Investigational
Matched Description: … It produces consistent but acceptable myelosuppression and cardiotoxic effects. ... It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in …
Matched Categories: … Indicators and Reagents ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 2376 - 2400 of 15640 in total